|
Showing 1 - 3 of
3 matches in All Departments
This volume provides a comprehensive overview of recent advances in
targeting glutamate signaling for the treatment of major
psychiatric and neurological disorders. It draws on the latest
findings in glutamate neurobiology and offers valuable insights
into the application of translational principles in neuroscience
drug discovery and development. In each chapter, glutamate as a
neurotransmitter, its receptors and transporters, and their
interplay with other neurotransmitters and neurotrophic factors,
are discussed in the context of a specific, highly prevalent and
disabling CNS disease. Most recent and detailed information is
provided on Ischemic Stroke, Chronic Stress, Major Depressive
Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD),
Posttraumatic Stress Disorder (PTSD), Alzheimer's Dementia,
Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD),
Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple
Sclerosis, Parkinson's Disease, Attention Deficit Hyperactivity
Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders.
Moreover, the book includes an extensive overview of glutamatergic
treatments already available on the market, and those which are
currently in pharmaceutical drug development pipelines. The primary
beneficiaries will be neurology and psychiatry specialists and
residents, neuroscientists, neuropharmacologists, pharmaceutical
industry and clinical research organization professionals,
academics, and clinicians working with psychiatric and neurological
patients with comorbidities such as cardiologists, pulmonologists,
and endocrinologists. This book will also appeal to psychiatry and
neurology subspecialists and clinicians working in neuroscience
labs seeking an easy-to-understand yet comprehensive overview of
contemporary evidence-based clinical insights backed by basic
science (preclinical) research evidence. Given its scope, the book
is also a unique and indispensable resource for both preclinical
and clinical neuroscientists, medical advisors, and clinical
research specialists in the pharmaceutical industry. In addition,
it will appeal to neuroscience and neuropsychopharmacology students
and guide them through the complexities of glutamate involvement in
the pathophysiology of the most common debilitating brain diseases
with high unmet medical needs.
Mounting evidence from preclinical and clinical research suggests
that the glutamatergic system is highly involved in the
pathophysiology of major neuropsychiatric disorders. All of these
scientific activities are a necessary first step, which translates
into opportunities in terms of development of new and improved
treatment strategies. Glutamate-based research over the last couple
of decades has provided novel insights into the pathogenesis of
both psychiatric disorders such as treatment resistant depression,
bipolar disorder, schizophrenia, PTSD, ADHD and neurological
disorders including Alzheimer's dementia, migraine, epilepsy, ALS
and neuropathic pain. Recent news developments also indicate
glutamate involvement in neurodevelopmental disorders such as
autism. In addition to the above, recent discoveries that several
novel therapeutic agents like riluzole, memantine, ketamine,
topiramate and lamotrigine possess glutamatergic properties as part
of their mechanism of action, further boosted the interest of drug
development companies and academic research centers to put more
effort into investigating novel therapeutically efficacious
compounds. Moreover, recent large "real life" clinical studies,
such as STAR*D, also looked into disease-associated glutamate
genetics and paved the way for the future creation of first
individualised pharmacogenetic treatments. The overall purpose of
this book is to provide the reader with expert opinions relating to
the most up-to-date information on glutamate's role in
pathophysiology of neuropsychiatric disorders and current and
future glutamatergic treatment strategies. The authors' hope that
this contribution will foster future research activities, which are
all ultimately aiming to improve quality of life in patients with
chronic, psychiatric and neurological disorders, thus enhancing
their contribution to society.
This volume provides a comprehensive overview of recent advances in
targeting glutamate signaling for the treatment of major
psychiatric and neurological disorders. It draws on the latest
findings in glutamate neurobiology and offers valuable insights
into the application of translational principles in neuroscience
drug discovery and development. In each chapter, glutamate as a
neurotransmitter, its receptors and transporters, and their
interplay with other neurotransmitters and neurotrophic factors,
are discussed in the context of a specific, highly prevalent and
disabling CNS disease. Most recent and detailed information is
provided on Ischemic Stroke, Chronic Stress, Major Depressive
Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD),
Posttraumatic Stress Disorder (PTSD), Alzheimer’s Dementia,
Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD),
Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple
Sclerosis, Parkinson’s Disease, Attention Deficit Hyperactivity
Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders.
Moreover, the book includes an extensive overview of glutamatergic
treatments already available on the market, and those which are
currently in pharmaceutical drug development pipelines. The
primary beneficiaries will be neurology and psychiatry specialists
and residents, neuroscientists, neuropharmacologists,
pharmaceutical industry and clinical research organization
professionals, academics, and clinicians working with psychiatric
and neurological patients with comorbidities such as cardiologists,
pulmonologists, and endocrinologists. This book will also appeal to
psychiatry and neurology subspecialists and clinicians working in
neuroscience labs seeking an easy-to-understand yet comprehensive
overview of contemporary evidence-based clinical insights backed by
basic science (preclinical) research evidence. Given its scope, the
book is also a unique and indispensable resource for both
preclinical and clinical neuroscientists, medical advisors, and
clinical research specialists in the pharmaceutical industry. In
addition, it will appeal to neuroscience and
neuropsychopharmacology students and guide them through the
complexities of glutamate involvement in the pathophysiology of the
most common debilitating brain diseases with high unmet medical
needs.
|
You may like...
Holy Fvck
Demi Lovato
CD
R92
Discovery Miles 920
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|